Login or Register to view
Mission-driven company targeting un-met clinical needs
Transaction Summary
Biosignals Diagnostics
-
Raising A$1.116M
-
A$0.171 per share
Investment Highlights
-
Biosignal monitoring company
-
Prevent, diagnose, and change outcomes for heart disease & stroke
-
ECGme device provides cost effective & real time solutions
-
Precision Healthcare
Company Overview
-
Heart disease remains the biggest killer in the world
death rates are estimated to double in the next 20 years
-
Biosignals Diagnostics provides solutions
Several global markets offering tailored solutions based on unmet needs or improved standard of care
-
ISV partner agreement with Oracle
signed on 5th April 2022
-
Demonstrations of the ECGme device
completed across twelve private meetings at the AusMedtech2022 conference
Products & Services
Biosignals Diagnostics offers solutions that target unmet clinical needs or improved standard of care in heart disease, with verified customers and markets.
Biosignals Diagnostics is a biosignal monitoring company, that addresses heart disease problems by integrating biometric data from specially designed, easily used devices and other sources such as imaging and genetics.
Product Suite
ECGME
- Small easy to use the device (the size of a credit card), fits in your pocket and when held with fingers on the sensors analyses real-time ECG signals
- Point-in-time ECG snapshot configurable for up to 10 minutes monitoring duration
- Converts to a 2 electrode 24hr on-body monitor for clinical use
- A TGA-approved Class 2a medical device
- Available July 2022
Transaction Overview
Raising A$1.116M at A$0.171 per share, with a pre-money valuation of A$8.9M,
6,521,739 shares on offer
Use of funds
20%ECGme Deployment
30%Platform Software Development
30%Marketing / Sales
20%3 Lead ECG3me Development
Additional Information
- Company Presentations
-
July 2022
Biosignals Teaser
-
September 2022
Information Brief Q3 2022
Team
- Management
-
Richard Rendell
Managing Director & Founder
-
Christopher Pendlebury
Chief Science Officer
-
Hayden Pitout
Chief Technical Officer
-
Kevin Hollingsworth
Company Secretary
-
Lexie Qin
Head of Product Engineering
-
Renee Ge
AI & Data Sciences Engineering
-
Stephan G Foy – MB ChB MD
Consulting Cardiologist & Clinical Advisor